Anbio Corp - NNNN Forward P/S Multiple
Anbio Biotechnology generates revenue through the supply of diagnostic systems and reagents to global medical centers. The business's forward P/S ratio shows a peak, after which the metric leveled off at 17.30. However, strict FDA oversight and logistical disruptions create risks. Meanwhile, moderate pricing power limits profitability unless the company implements unique patented developments.
Comprehensive metric breakdowns and analytics for Anbio Corp (NNNN)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Anbio Biotechnology|NNNN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Anbio Biotechnology|NNNN - Company Debts|Debts to Book Capitalization Anbio Corp|NNNN - Long-Term Debt Volume|Company Short-Term Debt Anbio Biotechnology|Quick Liquidity Indicator anbio.com
- financial results and valuation multiples details:
NNNN - Profit After Payment of Taxes|Projected Future Earnings Anbio Biotechnology|NNNN - Market Cap to Earnings|Forward P/E Multiple Anbio Tech|NNNN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Anbio Corp|NNNN - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Anbio Biotechnology|NNNN - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months anbio.com|NNNN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Anbio Biotechnology
- sales volume and revenue indicators:
Summary company analytics:Anbio NNNN
AI and robotics-driven automation of biomarker analysis is scaling revenue for Anbio Biotechnology (NNNN), which directly impacts the projected P/S trend. This indicator correlates market capitalization with forecasted sales, allowing investors to assess the premium paid for future growth and determine the asset's fair value during the intervals between official financial reports.
Analysis of competing companies
Price-to-Projected Revenue Ratio Agilent A|DGX: Market Cap to Projected Revenue|Illumina Corp - Forward P/S Multiple|EXAS: Price-to-Projected Revenue Ratio|RVTY: Forward P/S Multiple|BIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Sotera Health|Market Cap to Future Revenue Ratio Quidel Corporation QDEL|Forward Price-to-Revenue Multiple OPK (OPKO Corp)|CDNA (CareDx Health) - Forward Price to Sales|Forward P/S Multiple MRVI (Maravai LifeSciences)|fulgentgenetics.com - Price-to-Projected Revenue Ratio|Standard BioTools - Forward P/S Multiple|Market Cap to Expected Sales Ratio Cytek Biosciences Inc CTKB|OraSure Technologies Inc (OSUR) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Exagen (XGN)|Forward Price-to-Revenue Multiple MDXH|LUCD (luciddx.com) - Price to Expected Revenue Ratio|Forward P/S Multiple PRE|IMDX - Market Cap to Future Revenue Ratio|Forward P/S Multiple TRIB (Trinity Biotech)|PRPH - Forward Price-to-Revenue Multiple|Ainos, Inc. - Forward P/S Multiple|Forward Price to Sales CODX (codiagnostics.com)|HeartSciences (HSCS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue BMRA|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings Inc.|Market Cap to Future Revenue Ratio Onconetix Corporation ONCO|Price-to-Projected Revenue Ratio Virax Biolabs Group (VRAX)|Price-to-Projected Revenue Ratio BJDX (bluejaydx.com)|Price-to-Projected Revenue Ratio Aspira Women's Health Inc. AWH|Accelerate Diagnostics Inc. (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|Projected Price to Revenue Enzo Biochem, Inc. (ENZ)|FRES (fresh2.co) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Genetic Technologies Limited (GENE)|Price-to-Projected Revenue Ratio 23andMe|Market Cap to Projected Revenue PMD (Psychemedics Corp.)
